An interventional study of Prebiotic and Placebo in Mixed Fiber Supplementation for Healthy Adults, sponsored by Brown University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by Brown University · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a randomized, parallel-group interventional study evaluating the short-term gastrointestinal effects of a standardized multi-fiber supplement in healthy adults. Approximately 100 participants (50 per arm) aged 18 and older will be randomized to receive either the multi-fiber supplement or a control (flavoring agent only) daily for 10 days. Objectives include assessing effects on stool characteristics, specifically frequency and consistency, as well as changes in metagenomically inferred short-chain fatty acid production potential from the microbiota. Eligible participants must be free of chronic disease, acute illness, and recent antibiotic, probiotic, or prebiotic use. Total participation duration is 10 days.
Brown University is the lead sponsor of 290 studies on the registry; 40 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 19 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Dietary Supplement: Prebiotic
Dietary Supplement: Placebo
Formulated prebiotic supplement designed to be accessible to gut microbiota members and assist with bowel movement regularity
Placebo supplementation intervention, with only flavoring agents and no prebiotic fiber
Change in metagenomically inferred SCFA production potential
Through metagenomic sequencing analysis, change in relative abundance of short-chain fatty acid producing genes from sequenced timepoint stool samples will be assessed.
Time frame: Change observed from baseline sample (Day 0) to second sample (Day 10)
Bowel Movement Regularity
From a questionnaire that participants will fill out each day of the study, the number of bowel movements, the Bristol stool scale value, and amount of strain experienced during defecation will be assessed.
Time frame: Change observed over time from baseline (Day 0) through completion of the study (Day 10)
Observed changes in stool microbiome composition as profiled by metagenomic sequencing analysis
Statistically significant shifts in composition, diversity, and functionality
Time frame: Change observed from baseline sample (Day 0) to second sample (Day 10)
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Aug 2026; primary completion for Aug 2028, 24 months later.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Prebiotics